In cancer-associated thrombosis, DOACs reduce VTE and increase clinically relevant nonmajor bleeding vs. LMWH at 3 to 12 mo.
Where this comes from
- Record sourced from PubMed, PMID 41183346.
- Also identified by DOI 10.7326/ANNALS-25-04088-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
GIM/FP/GP: [Formula: see text] Oncology: [Formula: see text] Hematology: [Formula: see text].
Medical subject headings
- Hemorrhage
- Neoplasms
- Heparin, Low-Molecular-Weight
- Venous Thromboembolism
- Anticoagulants
- Factor Xa Inhibitors